Araştırma Makalesi

İndirekt Hiperbilirübinemi Tanısı ile Hospitalize Edilmiş Yenidoğanların Değerlendirilmesi

Cilt: 46 Sayı: 3 30 Eylül 2024
PDF İndir
EN TR

Evaluation of Newborns Hospitalized with a Diagnosis of Indirect Hyperbilirubinemia

Abstract

Objective: Neonatal jaundice is a common problem and is the most common cause of hospitalization. We aimed to determine the characteristics and etiological factors of late preterm and term newborns hospitalized due to indirect hyperbilirubinemia. Methods: Late preterm and term newborns hospitalized between January 1,2009 and December 31,2014 with a diagnosis of indirect hyperbilirubinemia were included. Demographic and clinical characteristics, duration, and patterns of treatment were obtained retrospectively. Etiological factors were determined. Result: Late preterm and term infants with indirect hyperbilirubinemia were included (n=412). 54.6% of the patients were male, 40.8 % were first babies, the mean gestational age was 38.3±1.1 weeks, and the mean birth weight was 3031±520 grams. 84.5 % were exclusively breastfed. The time of presentation was 4.6 ±2.6 days, and the serum total bilirubin level was 18.6 ±4.7 mg/dl. ABO incompatibility was found in 29 %, dehydration in 10.7 %, and Rh incompatibility in 7.1% of the patients. The mean duration of hospitalization was 3.1 ±2.2 days, and the mean duration of phototherapy was 44.8±22.8 hours. 16 patients received intravenous immunoglobulin. An exchange transfusion was performed in 14 patients. In the group with a serum total bilirubin level of ≥ 20 mg/dl, male gender and normal spontaneous vaginal delivery were statistically significantly higher than the group with a serum total bilirubin level below 20 mg/dl (p = 0.02 for both). Conclusion: Indirect hyperbilirubinaemia, which is common in the neonatal period, should be recognized early and is a treatable condition. We should promptly identify and treat the cause before complications arise.

Keywords

Destekleyen Kurum

yok

Etik Beyan

Etik Kurul Onayı: Çalışma XXX Etik Kurulu tarafından onaylanmıştır (Karar no:04/07, Tarih: 2015).

Teşekkür

yok

Kaynakça

  1. 1. Anderson NB, Calkins KL. Neonatal Indirect Hyperbilirubinemia. Neoreviews. 2020;21(11):e749-60.
  2. 2. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297-316.
  3. 3. Lo YS, Lu CC, Chen LY, Tsai LT. Clinical studies of neonatal hyperbilirubinemia treated with blood exchange transfusion. Gaoxiong Yi Xue Ke Xue Za Zhi. 1990;6(10):556-64.
  4. 4. Gartner LM, Herschel M. Jaundice and breastfeeding. Pediatr Clin North Am. 2001;48(2):389-99.
  5. 5. Newman TB, Maisels MJ. Evaluation and treatment of jaundice in the term newborn: a kinder, gentler approach. Pediatrics. 1992;89(5 Pt 1):809-18.
  6. 6. Burgos AE, Schmitt SK, Stevenson DK, Phibbs CS. Readmission for neonatal jaundice in California, 1991-2000: trends and implications. Pediatrics. 2008;121(4):e864-9.
  7. 7. Kaplan M, Bromiker R, Schimmel MS, Algur N, Hammerman C. Evaluation of discharge management in the prediction of hyperbilirubinemia: the Jerusalem experience. J Pediatr. 2007;150(4):412-7.
  8. 8. Polat A, Öktem F, Koç H. Evaluation of 963 neonates with hyperbilirubinemia. Türkiye clinical Pediatri 2.2. 1993:26-30.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Aile Hekimliği , Tıp Eğitimi

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

30 Eylül 2024

Gönderilme Tarihi

24 Temmuz 2024

Kabul Tarihi

10 Eylül 2024

Yayımlandığı Sayı

Yıl 1970 Cilt: 46 Sayı: 3

Kaynak Göster

AMA
1.Coşkun H, Bolat F. Evaluation of Newborns Hospitalized with a Diagnosis of Indirect Hyperbilirubinemia. CMJ. 2024;46(3):186-190. doi:10.7197/cmj.1520709